Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease

Supplemental Digital Content is available in the text.

[1]  Deepak L. Bhatt,et al.  A LEADER in the management of type 2 diabetes and cardiorenal disease. , 2020, The Journal of thoracic and cardiovascular surgery.

[2]  Deepak L. Bhatt,et al.  Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. , 2019, Journal of the American College of Cardiology.

[3]  Deepak L. Bhatt,et al.  Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. , 2019, Journal of the American College of Cardiology.

[4]  Deepak L. Bhatt,et al.  Aspirin for Primary Prevention of Cardiovascular Events. , 2019, Journal of the American College of Cardiology.

[5]  Deepak L. Bhatt,et al.  Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study , 2019, Clinical cardiology.

[6]  Marc P. Bonaca,et al.  Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial). , 2019, The American journal of cardiology.

[7]  Deepak L. Bhatt,et al.  Can We DECLARE a Victory against Cardio-Renal Disease in Diabetes? , 2018, Cell metabolism.

[8]  Deepak L. Bhatt,et al.  Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? , 2018, European heart journal.

[9]  Deepak L. Bhatt,et al.  External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry , 2018, European heart journal.

[10]  Deepak L. Bhatt,et al.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.

[11]  Deepak L. Bhatt,et al.  Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization , 2017, American heart journal.

[12]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[13]  Deepak L. Bhatt,et al.  Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. , 2016, Journal of the American College of Cardiology.

[14]  Marc P. Bonaca,et al.  Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.

[15]  Deepak L. Bhatt,et al.  Impact of Diabetes on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years from the REACH Registry , 2015 .

[16]  Deepak L. Bhatt,et al.  Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. , 2013, Journal of the American College of Cardiology.

[17]  Deepak L. Bhatt.  Antiplatelet therapy following myocardial infarction in patients with diabetes. , 2012, JAMA.

[18]  Deepak L. Bhatt,et al.  Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. , 2010, JAMA.

[19]  Deepak L. Bhatt,et al.  Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry , 2009, European heart journal.

[20]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[21]  Deepak L. Bhatt,et al.  One-year cardiovascular event rates in outpatients with atherothrombosis. , 2007, JAMA.

[22]  Deepak L. Bhatt,et al.  International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. , 2006, JAMA.